Kurzfassung

Open-Label, multicenter phase Ib/IIa study for the evaluation of Dasatinib (Sprycel) following induction and consolidation therapy as well as in maintenance therapy in patients with newly diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML).